DV Biomed Co. Ltd. (6539) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of DV Biomed Co. Ltd. TWD 11.15, price TWD 40.65, upside -72.6%, quality 60 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch DV Biomed Co. Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
DV Biomed Co., Ltd. manufactures and sells medical-grade skin care products in Taiwan and China. The company provides health and slimming services; and distributes medical aesthetic fillers and aesthetic medical equipment.
Show more
DV Biomed Co., Ltd. manufactures and sells medical-grade skin care products in Taiwan and China. The company provides health and slimming services; and distributes medical aesthetic fillers and aesthetic medical equipment. It also offers functional beverages and supplements, including beauty, slimming, supplements, and other products; skin care; and beauty products and services. The company was founded in 2011 and is based in Taipei, Taiwan.
Stock analysis
DV Biomed Co. Ltd. (6539) currently trades at 40.65 TWD, while our model-based Fair Value estimate is 11.15 TWD, implying the stock looks roughly 264.6% overvalued today.
Show more
Valuation
Bull case: the Dividend Discount group reads highest at a median of 14.60 TWD per share, and 0 of the 24 models we run sit above the 40.65 TWD price.
Bear case: the Earnings-Based group reads lowest at 2.64 TWD, and 24 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: 9.32 TWD (bear) to 11.15 TWD (bull), the price of 40.65 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
DV Biomed Co. Ltd. reported revenue of 794M TWD in FY2025 versus 1.8B TWD in FY2021, a compound −18.8%/yr. Reported net income was 7.7M TWD in FY2025, compounding −60.1%/yr from FY2021.
Key figures
Market cap 990M TWD (≈ $31.1M) · P/E ratio 12.9 · P/S ratio 0.13 · EPS (TTM) 3.16 TWD · Dividend yield 3.9% · Net margin 1.0% · Return on equity 15.0% · Return on assets (EBIT) 22.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 30% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −73%, 6539 screens richer than that median.
Fair Value models
Bear 9.32 TWDFair Value 11.15 TWDBull 11.15 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (1.15 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+38.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−24.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−15.2%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.8%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−48.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−51.9%
Dividend (yield on the price)3.9%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.15% → 2%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+25.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +23.2% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 631 stocks
Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score60 · Above median
Fair Value upside−73% · Bottom 25%
Profitability
Return on equity (TTM)15% · Top 25%
Return on assets7% · Top 25%
Net margin (TTM)10% · Above median
Operating margin (TTM)16% · Above median
Growth and dividend
Revenue growth0% · Below median
Dividend yield (TTM)3.9% · Top 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (TTM)12.9× · Cheapest 25%
P/B1.95× · Pricier than median
P/S (TTM)1.25× · Cheaper than median
P/FCF1.8× · Cheaper than median
EV/EBITDA10.1× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 15
FUTURE (revenue growth)2· sector 20
PAST (return on equity)60· sector 27
HEALTH (low debt)100· sector 96
DIVIDEND (yield)79· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is DV Biomed Co. Ltd. (6539) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 11.15 TWD versus a price of 40.65 TWD, about −73% upside (overvalued).
What is the fair value of 6539?
Our model-based fair value for DV Biomed Co. Ltd. is 11.15 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 40.65 TWD.
What is the quality score of 6539?
DV Biomed Co. Ltd. has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DV Biomed Co. Ltd. (6539)?
Our model-based price target is the fair value of 11.15 TWD (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 9.32 TWD, optimistic scenario 11.15 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the DV Biomed Co. Ltd. stock forecast for 2026?
Our models put fair value at 11.15 TWD, about −73% upside versus a price of 40.65 TWD (overvalued). Cautious scenario 9.32 TWD, optimistic scenario 11.15 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of DV Biomed Co. Ltd. (6539)?
DV Biomed Co. Ltd. reported trailing-twelve-month revenue of about 795M TWD (latest available figure, as of Sep 24, 2026).
Does DV Biomed Co. Ltd. pay a dividend?
DV Biomed Co. Ltd. currently shows a dividend yield of about 3.94% relative to its recent price (as of Sep 24, 2026).
What growth is priced into DV Biomed Co. Ltd. (6539)?
For today's price to be fair in a discounted-cash-flow model, DV Biomed Co. Ltd. would have to grow free cash flow by +25.2 % per year for five years (discount rate 9.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -15.2 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 6539 use?
Our models discount DV Biomed Co. Ltd. at 9.0 %: a base by market capitalisation (nano), damped by beta 0.07, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For DV Biomed Co. Ltd. that is +25.2 % per year a year over ten years, using the same discount rate (9.0 %) and the same formula as our fair value.
How much growth has DV Biomed Co. Ltd. (6539) delivered so far?
Over the past 5 years revenue at DV Biomed Co. Ltd. grew -15.2 % a year. The price currently implies +25.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of DV Biomed Co. Ltd. (6539) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into DV Biomed Co. Ltd. (+25.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of DV Biomed Co. Ltd. (6539)?
The free-cash-flow yield on the price is 1.73 %: that much free cash flow DV Biomed Co. Ltd. produces per unit of market value. When it exceeds the discount rate of our models (9.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of DV Biomed Co. Ltd. (6539)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DV Biomed Co. Ltd. it is 11.15 TWD per share (as of Sep 24, 2026), against a price of 40.65 TWD. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is DV Biomed Co. Ltd. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6539 trades above its calculated fair value: price 40.65 TWD, fair value 11.15 TWD, a gap of about −73% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6539?
No. The price is what the market pays today (40.65 TWD); the fair value is what the company's own numbers justify (11.15 TWD). For DV Biomed Co. Ltd. the two are 29.50 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is DV Biomed Co. Ltd. worth?
The market values DV Biomed Co. Ltd. at about 990M TWD (market capitalisation, as of Sep 24, 2026). Per share that is 40.65 TWD; our models calculate a fair value of 11.15 TWD per share.
What do the bullish and bearish scenarios say about 6539?
Our models span a range for DV Biomed Co. Ltd.: cautious scenario 9.32 TWD, base 11.15 TWD, optimistic 11.15 TWD per share (as of Sep 24, 2026, price 40.65 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6539?
DV Biomed Co. Ltd. trades at a price-to-earnings ratio of 12.9 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 11.15 TWD is built from several models across several years. Other multiples: P/B 2.0, P/S 1.2, EV/EBITDA 10.1.
How solid is the balance sheet of DV Biomed Co. Ltd. (6539)?
Balance-sheet figures for DV Biomed Co. Ltd. (as of Sep 24, 2026): return on equity 15.0%. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is 6539 from its 52-week high?
DV Biomed Co. Ltd. trades at 40.65 TWD, about 30% below its 52-week high of 58.16 TWD and 9% above the low of 37.37 TWD (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 11.15 TWD is for.
Which stocks are comparable to DV Biomed Co. Ltd.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DV Biomed Co. Ltd. stock attractive at the current price?
The data as of Sep 24, 2026: price 40.65 TWD, calculated fair value 11.15 TWD (−73%), Quality Score 60/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6539 calculated?
We run DV Biomed Co. Ltd. through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 11.15 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. DV Biomed Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DV Biomed Co. Ltd. (6539)?
The closing price on Sep 23, 2026 was 40.65 TWD. Our model-based fair value is 11.15 TWD, about −73% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DV Biomed Co. Ltd. right now?
The price sits above even our optimistic bull case (11.15 TWD). The favourable scenario is already priced in. Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of DV Biomed Co. Ltd.
How large is the market capitalisation of DV Biomed Co. Ltd. (6539)?
The market capitalisation of DV Biomed Co. Ltd. is 990M TWD (≈ $31.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DV Biomed Co. Ltd. (6539)?
The price-to-sales ratio of DV Biomed Co. Ltd. is 0.13 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of DV Biomed Co. Ltd. (6539)?
Earnings per share at DV Biomed Co. Ltd. are 3.16 TWD (price ÷ EPS = P/E 12.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of DV Biomed Co. Ltd. (6539)?
The dividend yield of DV Biomed Co. Ltd. is 3.9% (payout 50.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of DV Biomed Co. Ltd. (6539)?
The net margin of DV Biomed Co. Ltd. is 1.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DV Biomed Co. Ltd. (6539)?
The return on equity (ROE) of DV Biomed Co. Ltd. is 15.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DV Biomed Co. Ltd. (6539)?
On an EBIT basis the return on assets of DV Biomed Co. Ltd. is 22.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DV Biomed Co. Ltd. (6539)?
The operating margin of DV Biomed Co. Ltd. is 15.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DV Biomed Co. Ltd. (6539)?
Revenue at DV Biomed Co. Ltd. is growing +0.3% versus a year earlier (3y avg −24.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at DV Biomed Co. Ltd. (6539)?
Earnings per share at DV Biomed Co. Ltd. are growing −68.8% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch DV Biomed Co. Ltd. in the live analysis
One click puts DV Biomed Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
